Evidence map›Paper›PMID 42362880›Full record

ArticleAnnals of surgical oncology2026

Cyclin E1 Expression Predicts Poorer Outcome in HER2-positive Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy.

Yuko Ueki, Yoshiya Horimoto, Men Yuan, Rongrong Wu, Yumiko Ushiyama, Yumiko Ishizuka, Hiroko Onagi, Takuo Hayashi, Takahiko Kawate, Takashi Ishikawa and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Yuko UekiFaculty of Medicine, Department of Breast Oncology, Juntendo University, Tokyo, Japan.
Yoshiya HorimotoFaculty of Medicine, Department of Breast Oncology, Juntendo University, Tokyo, Japan. Horimoto.yoshiya.4m@tokyo-med.ac.jp.ORCID http://orcid.org/0000-0001-8935-0768
Men YuanFaculty of Medicine, Department of Human Pathology, Juntendo University, Tokyo, Japan.
Rongrong WuDepartment of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan.
Yumiko UshiyamaFaculty of Medicine, Department of Breast Oncology, Juntendo University, Tokyo, Japan.
Yumiko IshizukaFaculty of Medicine, Department of Breast Oncology, Juntendo University, Tokyo, Japan.
Hiroko OnagiFaculty of Medicine, Department of Human Pathology, Juntendo University, Tokyo, Japan.
Takuo HayashiFaculty of Medicine, Department of Human Pathology, Juntendo University, Tokyo, Japan.ORCID https://orcid.org/0000-0002-8544-9370
Takahiko KawateDepartment of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan.
Takashi IshikawaDepartment of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan.
Junichiro WatanabeFaculty of Medicine, Department of Breast Oncology, Juntendo University, Tokyo, Japan.ORCID https://orcid.org/0000-0001-9226-895X
Goro KutomiFaculty of Medicine, Department of Breast Oncology, Juntendo University, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmong HER2-positive breast cancer patients, those who do not achieve pathological complete response (non-pCR) after neoadjuvant chemotherapy (NAC) generally have poorer outcomes. Although additional postoperative therapies have been developed, it remains unclear which patients truly require treatment intensification. This study aimed to identify prognostic factors in non-pCR patients.

methodsOf 283 patients with HER2-positive invasive breast cancer treated with NAC, including anti-HER2 therapy between 2006 and 2023, 174 were classified as non-pCR. Of these, 37 patients developed distant metastases (Met group) and 137 remained metastasis-free (non-Met group). Gene expression profiling was performed by using pretreatment biopsies from six Met and six non-Met cases. Immunohistochemical validation was conducted in an independent cohort of 101 patients who did not achieve pCR.

resultsGene expression analysis identified multiple genes with differential expression between the Met and non-Met groups; MYCN, CCNE1, and IL6 were upregulated in the Met group, whereas KIT and ERBB4 were downregulated. Among these, MYCN and cyclin E1 showed concordant results at the protein level. Immune-related gene set analysis further suggested increased regulatory T-cell infiltration in the Met group. In the validation cohort, cyclin E1 positivity was significantly higher in the Met group (50% vs. 20%, P = 0.005), and cyclin E1-positive patients had significantly shorter disease recurrence-free survival (P = 0.005). Cyclin E1 expression was thus associated with poorer outcomes in HER2-positive breast cancer patients with non-pCR.

conclusionsThese findings support cyclin E1 as a prognostic biomarker that may contribute to risk stratification and individualized postoperative treatment strategies.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsCyclin EErb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyNeoplasm, ResidualOncogene ProteinsAdultAgedChemotherapy, AdjuvantFemaleFollow-Up StudiesGene Expression ProfilingHumansMiddle AgedBiomarkers, TumorCCNE1 protein, humanCyclin EERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesOncogene Proteins

Identifiers

PMID42362880

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.